The aim of this study was to identify whether there was any difference in patient, tumour, treatment or outcome characteristics between patients with skeletal or extra-skeletal Ewing's sarcoma. We identified 300 patients with new primary Ewing's sarcoma diagnosed between 1980 and 2005 from the centres' local database. There were 253 (84%) with skeletal and 47 (16%) with extra-skeletal Ewing's sarcomas. Although patients with skeletal Ewing's were younger (mean age 16.8 years) than those with extra-skeletal Ewing's sarcoma (mean age 27.5 years), there was little difference between the groups in terms of tumour stage or treatment. Nearly all the patients were treated with chemotherapy and most had surgery. There was no difference in the overall survival of patients with skeletal (64%) and extraskeletal Ewing's sarcoma (61%) (p = 0.85), and this was also the case when both groups were split by whether they had metastases or not.
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This large series has shown that the oncological outcomes of Ewing's sarcoma are related to tumour characteristics and patient age, and not determined by whether they arise in bone or soft tissue.
Ewing's sarcomas are rare, malignant tumours arising predominantly in the bones of children and young adults. [1] [2] [3] Current management includes a combination of chemotherapy and excision, with or without radiotherapy. 4, 5 Ewing's sarcoma is recognised to be a systemic disease, with between 20% and 30% of patients having detectable metastases at presentation. 6 Cure rates are now around 60% to 70% and are related to the presence of metastases at diagnosis, the size of the tumour and the response to chemotherapy. 2, 4, 5 It is well established, however, that a morphologically identical tumour can arise in soft tissues, and this is known as extra-skeletal Ewing's sarcoma. [7] [8] [9] These patients present with a mass in the soft tissues with an appearance similar to a soft-tissue sarcoma, but histology confirms the diagnosis of extraskeletal Ewing's sarcoma (Fig. 1) . The incidence of soft-tissue Ewing's sarcoma is generally accepted to be between 15% and 20% that of bony Ewing's. It is generally treated in the same way as Ewing's sarcoma of bone, and apart from rhabdomyosarcoma is one of the few soft-tissue sarcomas that respond well to chemotherapy. 10 The aim of this study was to assess the outcome of patients with extraskeletal Ewing's sarcomas and to compare these outcomes with those for patients with Ewing's sarcoma of bone in an attempt to establish whether they behave differently.
11-13

Patients and Methods
Between 1980 and 2005, 355 patients with a Ewing's sarcoma were treated at our centre; 40 patients were seen only for consultation, and 15 presented with recurrent disease following previous treatment elsewhere. This left 300 patients with newly diagnosed Ewing's sarcoma, of whom 253 (84%) had skeletal and 47 (16%) had extra-skeletal disease.
There were 126 females and 174 males, with a mean age of 16 years (1 to 71) and a mean follow-up of 87 months (0 to 295). The clinicopathological characteristics of these patients are summarised in Table I , which shows the differences between the patients with skeletal and extra-skeletal Ewing's sarcoma. There were 102 patients (34%) with metastases present at the time of diagnosis, 43 of these had metastases confirmed to the lung, but 59 had bony metastases.
The only significant difference between the two groups was their age distribution. The mean age of patients with skeletal Ewing's was ten years younger than those with extraskeletal disease. The size of the tumours was almost identical, as was the gender distribution and the prevalence of metastatic disease at diagnosis. The three most common sites for skeletal Ewing's were the femur 22% (67 of 253), pelvis 21% (64 of 253) and tibia 12% (37 of 253). Of the extra-skeletal Ewing's, 21 (45%) were located in the thigh.
All patients were treated according to the relevant national or European protocol available at the time. [14] [15] [16] Those under the age of 40, and most of those over 40 received chemotherapy and excision when this could be achieved without major morbidity. The chemotherapy usually consisted of an induction regimen using vincristine, adriamycin, ifosfamide and etoposide, continuing after surgery with a regimen dictated by the trial they were in. [14] [15] [16] Radiotherapy was used if the tumour was felt to be inoperable, or if there was a positive margin following excision, or a poor response (< 90% necrosis) of the tumour to neoadjuvant chemotherapy. Percentage necrosis was defined by the criteria of Salzer-Kuntschik et al. 17 Adjuvant and definitive radiotherapy was given according to national guidelines. We reviewed data from a prospective database, and if there was inadequate information, the patient records were consulted. We collected patient, tumour, treatment and outcome data for all patients, concentrating especially on previously identified prognostic factors, namely stage of disease at diagnosis, age, size of the tumour, location, treatment and response to chemotherapy. In patients who underwent excision, margins were assessed as being either clear (wide or radical) or involved (intralesional or marginal). Central tumours were classified as those involving the trunk, chest wall or pelvis. Most patients underwent follow-up at our centre or under a shared care arrangement. For patients who had been lost to follow-up, their survival data were confirmed through the Cancer Intelligence Network.
All but one of the 300 patients was treated with chemotherapy. This patient, with a 5 cm subcutaneous extraskeletal Ewing's sarcoma overlying the deltoid, had it excised before the diagnosis was made. She had adjuvant radiotherapy and did not have chemotherapy because of other comorbidity.
A total of 216 (72%) patients underwent surgery, which included 183 (72%) with skeletal Ewing's and 33 (70%) with extra-skeletal Ewing's. The types of surgery carried out in the two groups are shown in Table I. A total of 84 patients did not undergo surgery. Of the 70 (28%) with skeletal Ewing's who did not undergo surgery, all had radiotherapy, usually for progressive disease (45 patients) or because surgery would have been very disabling (e.g. large pelvic tumours) (25 patients).
Of the 14 (30%) with extra-skeletal Ewing's sarcoma who did not have surgery, 11 had progressive metastatic disease and so had radiotherapy for local control, whereas three patients had no residual tumour identifiable after chemotherapy and had radiotherapy alone. Adjuvant radiotherapy was used after surgery in 99 cases (33%), usually because of either a poor response to chemotherapy or an involved margin of excision, or both. Statistical analysis. Differences between groups were assessed using the chi-squared or the t-test. Overall survival and the rate of local recurrence were calculated using the KaplanMeier method and the impact of prognostic factors was assessed using the log-rank test. 18 Multivariate analysis was performed using Cox's proportional hazard's method, 19 with variables chosen using a forward conditional stepwise approach. Relative risks were calculated using a proportional hazards model, with only the noted covariate in the model.
Significance was set at p < 0.05 for two-sided tests. Survival time was calculated from the time of diagnosis. Endpoints were taken at the time of death or the last documented time the patient was known to be alive. Patients who died of unrelated causes were considered to have been censored.
Results
Overall survival. At the last follow-up, 129 patients (43%) had died of their disease. For the entire cohort of 300 patients, the overall survival was 64% at five years and 56% at ten years, respectively. Patients who presented with bone metastases had a five-year survival rate of 12%, and for those presenting with lung metastases survival was 23% (p = 0.02); those without metastases at presentation had a better survival at 78% (p < 0.0001). There was no difference in the five-year survival between patients with skeletal (64%) or extra-skeletal Ewing's (61%) sarcoma (p = 0.85) (Fig. 2 ). There were almost identical survival rates for patients with or without metastases in the two groups (Fig. 3) . Table II shows the univariate analysis of prognostic factors associated with overall survival. Local recurrence. A total of 36 patients (12%) developed local recurrence at a mean of 28 months (0 to 149). The five-and ten-year risk of local recurrence for the cohort of 300 patients was 14% and 15%, respectively. Of the local recurrences, 34 (13%) were in patients with skeletal Ewing's and two (4.2%) in patients with extra-skeletal Ewing's (p = 0.075). Patients who underwent excision had a much lower rate of local recurrence than those treated with radiotherapy alone (10% vs 35%) (p < 0.001).
Patients with a poor response to chemotherapy (< 90% necrosis) had a higher rate of local recurrence (16%) than those with > 90% necrosis (8% local recurrence, p = 0.09).
Patients who had adequate local treatment (excision with wide margins and good necrosis, or the addition of radiotherapy if they had either closer margins or poor Kaplan-Meier curve of overall survival of patients with Ewing's sarcoma in relation to tissue type (skeletal vs extra-skeletal) and presence of metastases at diagnosis.
necrosis) had a 9% risk of local recurrence, compared to a 21% risk of local recurrence in the group who did not have radiotherapy but had either a close margin or a poor response to chemotherapy (< 90% necrosis) (p = 0.02).
Patients with tumours of the pelvis had an 11% rate of local recurrence following surgical treatment alone, 25% if treated with radiotherapy alone, and 23% if they had both surgery and radiotherapy.
Discussion
The aim of this study was to investigate whether there is any difference in the behaviour of the tumour in patients with skeletal and extra-skeletal Ewing's sarcoma. Although there is an extensive literature on bony Ewing's, there is little on extra-skeletal Ewing's sarcoma, and no previous study comparing the two in a similarly treated adult population. Our study has confirmed that there are remarkable similarities between skeletal and extra-skeletal Ewing's sarcoma, both in the size of the tumour at diagnosis and in the proportion of patients with metastases at diagnosis. Our population of patients with skeletal Ewing's is similar to other reported series in age distribution, 15 but our patients with extra-skeletal Ewing's sarcoma were considerably older, albeit nowhere near as old as the median age for patients with soft-tissue sarcomas in general, which is around 50 years. 20 Management of the two groups was along similar lines, using chemotherapy and surgery in the majority of cases. In both groups a small percentage had progressive metastatic disease and therefore did not undergo surgery to the primary site and merely had radiotherapy. Radiotherapy was also used for local control in selected cases of bony pelvic Ewing's, where there remains uncertainty as to the benefits of surgery against radiotherapy in obtaining local control, and whether this influenced subsequent survival. [21] [22] [23] Local control was similar for both types of tumour, excision with or without radiotherapy, not surprisingly, produced better results than radiotherapy alone. The failure to show any effect of margins on local control is not surprising, as patients with marginal or intralesional margins were almost always treated with radiotherapy. This study does, however, confirm the importance of appropriate treatment in reducing local recurrence, using radiotherapy if there is either a close margin of excision or a poor response to chemotherapy. Outcomes in terms of overall survival were also remarkably similar when the two groups were compared. In both skeletal and extra-skeletal Ewing's sarcoma, patients with metastases at diagnosis had a poorer outcome than those without.
The main limitation of this study is that it took place over 25 years, and during that time treatment for Ewing's sarcoma has evolved. Chemotherapy regimens have become more sophisticated and less toxic, with small increases in survival. 24, 25 Our patients were all treated according to the contemporary protocols and will therefore have had standard chemotherapy regimens. Patients over the age of 40 are usually excluded from most Ewing's chemotherapy trials, but in this case all but one patient received chemotherapy, although in many cases a reduction in the dose will have been needed. Local therapy will also have been influenced by the contemporary protocol, with an increasing use with time, of a combination of surgery and radiotherapy as opposed to radiotherapy alone. The low number of extra-skeletal Ewing's sarcomas has also reduced the power of this study, and this is the reason why there are so few reports on this condition.
Our results are consistent with those of other series extending over such a long time. The overall survival rate for the 300 patients was 64% at five years and 56% at ten years. These figures are similar to other studies such as those of Nesbit et al 6 and Picci et al, 10 who have shown fiveyear survival rates of between 50% and 60%, respectively. Gururangan et al, 26 in a series of 17 children with extraskeletal Ewing's sarcoma, showed similar survival rates to another group of children with skeletal Ewing's using a consistent Ewing's-directed combined therapy. They concluded that a similar multimodal treatment method could be applied for both groups of patients. The survival of our patients correlated with previously known prognostic factors, including the size and site of the tumour. Patient age was also important, with those < 16 years of age having better rates of survival. This finding is consistent with other papers that have looked at either skeletal or extra-skeletal Ewing's sarcoma. Ahmad et al 11 reported a five-year survival of 61% for 24 patients with extra-skeletal Ewing's sarcoma, with better survival for patients < 16 years and those who underwent wide excision. Other studies have also confirmed the improved results, both for younger patients and for tumours in the extremity. 4, 6, 12 Poorer outcomes for patients with central tumours is likely to be because of their greater size at presentation and the increased risk of metastatic spread. 20 The European Intergroup Cooperative Ewing's Sarcoma Study 27 showed that patients who presented with metastases had a five-year risk-free survival of 22%, compared to 55% in those without. In addition, they showed that patients with bony metastases with or without lung metastases had poorer survival, which matched the results from our series.
Like others, we found that excision improves local control and that local recurrence in patients treated with radiotherapy alone is around 25%. 24 Because of the small size of our series we could not identify any prognostic impact of margins of excision on local recurrence, although others have found closer margins to be predictive of local recurrence. [28] [29] [30] In conclusion, this series has shown that the oncological outcomes of Ewing's sarcoma are related to tumour characteristics and patient age, and are not determined by the tissue component. Patients with skeletal and extra-skeletal Ewing's sarcoma have almost identical outcomes when treated according to the same protocol.
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